日本肺癌手术病例登记:第7版与第8版TNM分期的预后信息与安全性分析
该研究回顾性分析2010年日本297家医院18,973例原发性肺癌手术病例,评估人口学、安全质量及第7版与第8版TNM分期的预后相关性。结果显示5年总生存率74.7%,无病生存率67.8%,第8版TNM分期对临床IA/IB期有更细化的预后分层。
要点
- 5年总生存率74.7%,无病生存率67.8%。
- 第8版TNM将第7版临床IA/IB期细分为0–IA3及IA1–IIA期,预后分层更优。
- 30天和90天死亡率分别为0.43%和1.26%。
核心结论
- 日本肺癌手术结果改善,第8版TNM分期通过分期迁移和预后分层得到支持。
研究设计与样本
- 回顾性收集2010年手术的原发性肺癌患者临床病理资料,2016年分析,来自297家医院共18,973例(男11,771例,平均年龄68.3岁)。
主要发现
- 肿瘤小于2.0 cm者占39.0%,有限切除占22.7%。
- 30天和90天死亡率分别为0.43%和1.26%。
- 5年总生存率和无病生存率分别为74.7%和67.8%。
- 第7版病理分期5年生存率:IA期88.9%,IB期76.7%,IIA期64.1%,IIB期56.1%,IIIA期47.9%,IIIB期30.2%,IV期36.1%。
- 第8版临床分期5年生存率:0期97.0%,IA1期91.6%,IA2期81.4%,IA3期74.8%,IB期71.5%,IIA期60.2%,IIB期58.1%,IIIA期50.6%,IIIB期40.5%,IIIC期37.5%,IVA/B期36.0%。
关键数值与推荐
- 第7版病理分期5年生存率(本研究2010年 vs 前次研究2004年):IA期88.9% vs 86.8%,IB期76.7% vs 73.9%,IIA期64.1% vs 61.6%,IIB期56.1% vs 49.8%,IIIA期47.9% vs 40.9%,IIIB期30.2% vs 27.8%,IV期36.1% vs 27.9%。
- 第8版临床分期5年生存率:0期97.0%,IA1期91.6%,IA2期81.4%,IA3期74.8%,IB期71.5%,IIA期60.2%,IIB期58.1%,IIIA期50.6%,IIIB期40.5%,IIIC期37.5%,IVA/B期36.0%。
- 再分期后,第7版临床IA和IB期总生存率分别被第8版分层为0–IA3期和IA1–IIA期。
临床怎么用
- 第8版TNM分期对早期肺癌(临床IA/IB)提供更细预后分层,可辅助临床决策。
局限性
- 回顾性研究,数据收集于2016年,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Japanese Joint Committee of Lung Cancer Registry performed the fourth nationwide registry study of surgical cases. Demographics, safety and quality, prognostic information, and correlations between the seventh and the eighth editions of the TNM classification were investigated. The principal results were compared with those of previous Japanese Joint Committee of Lung Cancer Registry studies. METHODS: The clinicopathologic profiles, staging, and prognosis of patients who had an operation for primary lung cancer in 2010 were retrospectively collected in 2016 and analyzed. RESULTS: The cohort consisted of 18,973 patients from 297 hospitals (11,771 males, mean age 68.3 years). Tumor smaller than 2.0 cm was seen in 39.0% of patients, and limited resection was performed in 22.7%. The 30- and 90-day mortality rates were 0.43 and 1.26%, respectively. The overall and disease-free survival rates at 5 years were 74.7 and 67.8%, respectively. The respective 5-year survival rates by pathological stage in the seventh edition in the present study (2010) and in the previous study (2004) were 88.9% and 86.8% for stage IA, 76.7% and 73.9% for stage IB, 64.1% and 61.6% for stage IIA, 56.1% and 49.8% for stage IIB, 47.9% and 40.9% for stage IIIA, 30.2% and 27.8% for stage IIIB, and 36.1% and 27.9% for stage IV. The 5-year survival rates by clinical stage in the eighth edition in the present study were 97.0% for stage 0, 91.6% for stage IA1, 81.4% for stage IA2, 74.8% for stage IA3, 71.5% for stage IB, 60.2% for stage IIA, 58.1% for stage IIB, 50.6% for stage IIIA, 40.5% for stage IIIB, 37.5% for stage IIIC, and 36.0% for IVA/B. With restaging, the overall survival rates of clinical stage IA and IB in the seventh edition were stratified into stages 0 to IA3 and stages IA1 to IIA in the eighth edition, respectively. CONCLUSIONS: This study demonstrates improved surgical results for lung cancer in Japan. The TNM revision for the eighth edition was supported by the assessment of stage migration from the previous edition and the prognostic stratification.
引用
- Okami J, Shintani Y, Okumura M, et al. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. J Thorac Oncol. 2018. PMID: 30316011. doi:10.1016/j.jtho.2018.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。